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Background: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle
East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the
rate of relapse and disability progression in relapsing-remitting multiple sclerosis (MS). Natalizumab is recommended
for patients who fail first-line disease-modifying therapy or who have very active disease. Progressive multifocal
leukoencephalopathy is a rare, serious adverse event associated with natalizumab.
We aim to develop regional recommendations for the selection and monitoring of MS patients to be treated with
natalizumab in order to guide local neurological societies.
Methods: After a review of available literature, a group of neurologists with expertise in the management of MS
met to discuss the evidence and develop regional recommendations to guide appropriate use of natalizumab in
the region.
Results: Disease breakthrough is defined as either clinical (relapse or disability progression) or radiological activity
(new T2 lesion or gadolinium-enhancing lesions on MRI), or a combination of both. Natalizumab is recommended
as an escalation therapy in patients with breakthrough disease based on its established efficacy in Phase III studies.
Several factors including prior immunosuppressant therapy, anti-John Cunningham virus (JCV) antibody status and
patient choice will affect the selection of natalizumab. In highly active MS, natalizumab is considered as a first-line
therapy for naive patients with disabling relapses in association with MRI activity. The anti-JCV antibody test is used
to assess anti-JCV antibody status and identify the risk of PML. While seronegative patients should continue treatment
with natalizumab, anti-JCV antibody testing every 6 months and annual MRI scans are recommended as part of patient
monitoring. In seropositive patients, the expected benefits of natalizumab treatment have to be weighed against the risks
of PML. Clinical vigilance and follow-up MRI scans remain the cornerstone of monitoring. After 2 years of natalizumab
therapy, monitoring should include more frequent MRI scans (every 3–4 months) for seropositive patients, and the
risk-benefit ratio should be reassessed and discussed with patients.
Conclusions: Recommendations have been developed to guide neurologists in the Middle East and North Africa on
patient selection for natalizumab treatment and monitoring.
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Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disorder affecting the central nervous system. His-
torically, the Kurtzke classification has designated
many Middle Eastern countries as being low-risk zones
for MS, but recent studies have shown that the crude
incidence of MS in this region ranges from 31–85 per
100,000 individuals, and that the annual incidence is
increasing [1-4]. Interferon-beta is generally regarded
as the first-line treatment for MS, with natalizumab
and fingolimod used as second-line agents in the case
of treatment failure with interferon-beta [1].
Natalizumab, a highly specific α4-integrin antagonist, has
recently been registered across the Middle East and North
Africa (MENA) region. It is recommended as a single
disease-modifying therapy (DMT) in patients with highly
active relapsing-remitting MS to prevent relapses and delay
progression of disability. Natalizumab is indicated in pa-
tients who fail to respond to a full and adequate course
(normally at least 1 year of treatment) of interferon-beta or
glatiramer acetate, or for those who have rapidly evolving,
severe relapsing-remitting MS. Failure to respond is defined
as at least one relapse in the previous year on therapy and
at least nine T2-lesions in cranial magnetic resonance im-
aging (MRI) or at least one gadolinium-enhancing (Gd) le-
sion. Rapidly evolving severe relapsing-remitting MS can be
defined by at least two disabling relapses in 1 year and at
least one Gd-enhancing lesion on brain MRI or a signifi-
cant increase of T2 burden [5].
Natalizumab improves clinical and MRI outcomes
and reduces the rate of relapse and disability progres-
sion in relapsing-remitting MS [6-9]. The Phase III
AFFIRM (Natalizumab Safety and Efficacy in Relapsing-
Remitting MS) study showed that monotherapy with
natalizumab for 2 years decreased the annualised relapse
rate (ARR) by 68% (p < 0.001) and the disability progres-
sion rate (sustained for 3 months) by 42% (p < 0.001) com-
pared with placebo [6]. For MRI outcomes, a 92% decline
in the number of Gd-enhancing lesions during the second
year (p < 0.001), an 83% decrease in the number of new or
enlarging T2-hyperintense lesions over 2 years (p < 0.001),
and a 76% fall in new T1-hypointense lesions were seen
[7]. Natalizumab was found to be generally safe and well
tolerated [6]. The advent of newer therapies such as natali-
zumab has led to more ambitious aims of MS treatment,
with freedom from measured disease activity and im-
provement being possible [10,11].
Progressive multifocal leukoencephalopathy (PML) is a
rare, serious adverse event associated with natalizumab.
PML is an opportunistic infection of the central nervous
system that is caused by John Cunningham virus (JCV).
The virus replicates in glial cells of the brain, leading to
lytic death of oligodendrocytes. PML is very rare in im-
munocompetent people, typically occurring in severelyimmunocompromised patients such as those with HIV
infection, malignant disease or organ transplants. It may
present with any combination of weakness, speech dis-
turbances, limb incoordination, cognitive deficits and
visual impairment, usually resulting in death or severe
disability [12]. Three cases of PML were identified in the
pivotal natalizumab clinical trials.
Post-marketing reports of PML cases have been system-
atically collected, and risk management strategies have
been developed on the basis of an increased risk in patients
with seropositive anti-JCV antibodies, with longer duration
of natalizumab treatment and with prior immunosuppres-
sive therapy [13]. The risk of PML among patients with
none of these risk factors is very low. There is now evi-
dence to suggest that outcomes of PML may be better in
patients in whom the condition is detected and treated
early, even before the presence of clinical symptoms [14].
Our aim is to guide local neurological societies in the
MENA region by developing recommendations for the se-
lection and monitoring of MS patients to be treated with
natalizumab.
Methods
After a review of available literature, a group of neurol-
ogists with expertise in the diagnosis and management
of MS met to discuss the updated evidence and to de-
velop regional recommendations to guide appropriate
use of natalizumab in the region. The panel used the
revised 2010 Mcdonald diagnostic criteria for MS in
the discussion and recommendations [15]. The neurol-
ogists reviewed evidence on the efficacy of natalizumab
in comparison with other MS therapies, and on the risk
of PML and its early detection and management. Rele-
vant cases were discussed to highlight clinical decision
points, and agreement was reached on key topics
through voting on a series of questions on the posi-
tioning of natalizumab in the MS treatment paradigm.
Several important factors were discussed, including appro-
priate patient selection, routine safety monitoring, and
an understanding of both early recognition and timely
management of PML. Disease breakthrough was defined as
either clinical (relapse or disability progression) or radio-
logical activity (new T2 lesion or Gd-enhancing lesions on
MRI) or a combination of both. Relapse was defined as new
or recurrent neurologic symptoms not associated with fever
or infection that lasted for at least 24 hours and were ac-
companied by new neurological signs found by the examin-
ing neurologist. Disease progression was defined as an
increase of at least 1.5 points on the Expanded Disability
Status Scale (EDSS) score [16]. Disabling relapse was de-
fined as a relapse with a residual disability, which was
defined as incomplete recovery at 1 month from a relapse
[17,18]. As the panel did not conduct any novel experimen-
tal research, no ethics approval was necessary.
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Efficacy of natalizumab
The goals of MS treatment have evolved as new therapies
have become available. While initial therapies reduced
symptoms and the next generation slowed disease pro-
gression, the current aim is to stop disease progression
and to achieve freedom from disease activity [10]. Sus-
tained improvement in neurological disability has been
shown to be possible [11]. An EDSS score of 3 seems to
be a turning point in the development of disability, with
progression being more rapid and difficult to stop after
that point [19]. Key decision points in MS treatment are
therefore initiation of therapy and escalation of therapy.
While results from different clinical studies cannot be dir-
ectly compared, the 68% reduction in ARR seen with natali-
zumab [6] is higher than those reported for glatiramer
acetate and interferon-beta 1a and 1b (29–34%) [20-23] or
fingolimod (54%) [24]. Similarly, natalizumab reduced dis-
ability progression by 42% sustained at 12 weeks and by
54% sustained at 24 weeks [6], whereas fingolimod per-
formed comparably to interferon (37% reduction sustained
at 24 weeks with both) [23,24]. In a subgroup analysis of
AFFIRM data, patients with very active MS (>2 relapses in
previous year and Gd-enhancing lesions at baseline) had re-
ductions of 81% in ARR, and 53% and 64% reduction in
sustained (12 and 24 weeks, respectively) disability progres-
sion with natalizumab [25]. Equivalent figures for fingoli-
mod were 63% and 22% [26]. Five times more patients
were free from disease activity with natalizumab versus pla-
cebo (37% vs. 7%) compared with 2.5 times for fingolimod
(33% vs. 13%) [10].
The efficacy of natalizumab reported from the clinical tri-
als is supported by real-world data. The Tysabri Observa-
tional Program (TOP) is an open-label, observational study
being conducted in Europe, Australia and Canada, with
3976 patients from 15 countries enrolled by December
2011. The ARR was reduced from 1.99 (95% CI 1.96–2.03)
at baseline to 0.26 (95% CI 0.23–0.30; p < 0.0001) after
3 months of natalizumab treatment and was maintained at
that rate at 4 years [27]. EDSS was stable over 4 years, in
both patients with a high (4.5) or low (2.0) starting median
EDSS, and more patients had confirmed improvement ra-
ther than disability progression [28]. In the TYNERGY
study, natalizumab was prescribed in a real-life setting,
and the Fatigue Scale for Motor and Cognitive Functions
(FSMC) showed a reduction in 9.0 points (p < 0.0001) after
12 months, corresponding to a reduction from severe to
moderate fatigue [29]. Scores for quality of life, sleepiness,
depression, cognition and disability progression were all im-
proved from baseline (all p < 0.0001), and walking speed as
measured by the 6-minute walk-test also increased at
month 12 (p = 0.0016) [29]. In the Swedish IMSE (Immu-
nomodulation and Multiple Sclerosis Epidemiology) study,
a significant improvement in Symbol Digit Modalities Test(SDMT) score (from 49.7 to 55.6; p < 0.05) was seen over
24 months’ natalizumab treatment [30]. In a Belgian cohort,
natalizumab increased freedom from disease activity in
relapsing-remitting MS patients after previous therapy fail-
ure, with 62% being free of disease activity after 44 weeks.
EDSS was marginally worse in 4% of patients, stable in
40%, marginally improved in 27% and improved by ≥1
point in 29% [31].
There is no level 1 evidence to support the use of natali-
zumab in patients under the age of 18 years, and this ther-
apy is not licensed for use in paediatric patients. However,
some studies have evaluated its use in paediatric cohorts
[32-34]. In an Italian cohort of 55 patients (mean age
14.4 years), significant improvement in mean EDSS scores
was reported (from 2.7 to 1.9 at the last visit; p < 0.001)
[32]. Similarly, in a Spanish cohort of nine patients (mean
age 15.3 years), eight demonstrated a median improve-
ment in EDSS score from 3.0 to 1.0, and a reduction in
median ARR from 3.0 to 0 [33]. Natalizumab also appears
to be generally well tolerated in this patient population
[34]. In light of this evidence, the experts suggest that the
use of natalizumab would need to be carefully considered
and discussed on a case-by-case basis.
Discontinuation of natalizumab
When considering the withdrawal of natalizumab therapy,
the physician should consult with patients on an individual
basis, reassess the benefit/risk of natalizumab versus burden
of disease and alternative therapies, and increase alertness
and monitoring. Studies evaluating the effect of natalizu-
mab interruption show that MS activity may return to pre-
treatment levels within 4–7 months, and that the levels of
disease activity did not exceed those noted during the trials
in subjects randomised to placebo [35]. The pattern of the
return of MS disease activity was consistent with known
pharmacokinetic and pharmacodynamic properties of nata-
lizumab and did not show evidence of rebound [35].
PML risk assessment
The observed PML incidence in patients who received a
mean of 17.9 monthly doses of natalizumab in the clinical
trials was 1.00 per 1000 natalizumab-treated patients (95%
CI 0.20–2.80) [36]. The post-marketing rate is calculated
as the number of PML cases in patients who have had at
least one dose of natalizumab. Worldwide post-marketing
data from 23 November 2004 to 31 March 2013 com-
prised 279,196 patient-years of natalizumab exposure.
Overall, 115,400 patients were treated in this period:
83,000 patients for at least 12 months, 59,100 for at least
24 months, 41,100 for at least 36 months and 26,600 for at
least 48 months. As of 6 May 2013, 359 confirmed cases
of PML had occurred, giving an overall post-marketing
rate of 3.04 (95% CI 2.74–3.38) per 1000. The rate in-
creases with number of natalizumab infusions, from 0.05/
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with a tripling of risk at around 24 infusions (Figure 1). Of
the 359 cases, 123 were from the US, 212 from Europe
and 24 from the rest of the world; 83 (23%) patients died
and 276 (77%) were still alive as of 6 May 2013 [37].
JCV infection is one of the key factors for PML develop-
ment. A two-step enzyme-linked immunosorbant assay
(ELISA) has been developed to detect the presence of
anti-JCV antibodies in serum or plasma to help identify
patients who have been exposed to JCV [38]. This assay is
now being used as a risk stratification tool in natalizumab-
treated patients. The prevalence of anti-JCV antibodies in
MS patients is approximately 50–60% [38]. Preliminary
data suggest that 2–3% of patients seroconvert annually
(i.e. change from anti-JCV antibody negative status to
positive status and remain positive over time) [39]. Of the
confirmed PML cases, 139 had pre-PML samples available
for anti-JCV antibody testing and 138 of these tested posi-
tive prior to diagnosis of PML (6–187 months). One pa-
tient tested negative 9 months before PML diagnosis, and
no further samples were available; another patient tested
negative 9 months before PML diagnosis and positive
6.5 months before diagnosis [37].
Risk stratification based on natalizumab exposure, anti-
JCV antibody status and prior immunosuppressive therapy
offers an opportunity for personalised management of MS
patients. Figure 2 shows the stratification of PML risk in pa-
tients treated with natalizumab. It can be seen that the risk
of PML in anti-JCV antibody negative patients is very low
(0.07/1000); duration of therapy and immunosuppressive
history are not relevant factors in this patient segment.
Benefits of early PML detection and treatment
Neurologists need to exercise clinical vigilance for the
signs and symptoms of PML. Onset is usually subacute,Figure 1 Natalizumab PML risk estimates by treatment epoch [37]. Th
mean of 17.9 monthly doses of natalizumab was 1.00 per 1000 natalizumab
calculated as the number of PML cases in patients who have had at least o
calculated based on natalizumab exposure through 30 April 2013 and 359 con
as the number of PML cases divided by the number of patients exposed to naoccurring over several weeks, and is progressive (com-
pared with the typical acute onset of an MS relapse). Clin-
ical presentation can include visual change and motor or
behavioural changes [14]. Recent changes in behaviour
or personality, hemiparesis, language disturbances, retro-
chiasmal visual deficits and onset of seizures should alert
the clinician to possible PML. Relatives may notice subtle
changes that are not apparent to the clinician. PML lesions
can be detected on MRI scans. In a review of 22 of the first
40 post-marketing cases of PML, the most frequent lesion
pattern in early scans from PML patients was that of large
(>3 cm, 15/18), subcortical (18/18), T2 or fluid-attenuated
inversion recovery hyperintense (18/18), T1-hypointense
(17/18), and diffusion-hyperintense (15/15) lesions, with a
sharp border towards the grey matter and an ill-
defined border toward the white matter (18/18) on T2-
weighted images. Contrast enhancement was detected
in 41% (7/17) of the cases on the first scan at clinical
presentation [40]. A diagnosis of PML can usually be
confirmed by cerebrospinal fluid (CSF) analysis using
JCV DNA amplification by the polymerase chain reac-
tion (PCR) technique with a sensitivity of 80% and a
specificity approximating 100% [12].
PML is treated by immune reconstitution. Plasma ex-
change rapidly reduces natalizumab concentrations in
serum and restores leukocyte function [41]. Several
courses of plasma exchange or immunoadsorption have
been used to eliminate natalizumab in post-marketing
PML cases [42]. However, this treatment is often followed
by immune reconstitution inflammatory syndrome (IRIS),
which can lead to serious neurological complications or
death. IRIS can be successfully treated with high-dose ste-
roids [13]; prophylaxis of IRIS with corticosteroids has not
been systematically evaluated, but given the severe nature
of IRIS and its consistent presentation in most patients,e observed clinical trial PML incidence in patients who received a
-treated patients (95% CI 0.20–2.80) [36]. The post-marketing rate is
ne dose of natalizumab. Incidence estimates by treatment epoch are
firmed cases as of 6 May 2013. The incidence for each epoch is calculated
talizumab.
Figure 2 PML risk stratification in natalizumab-treated MS patients [37]. Based on natalizumab exposure and 285 confirmed PML cases as
of 5 September 2012. Prior immunosuppression (IS) data in overall natalizumab-treated patients based on proportion of patients with IS use prior
to natalizumab therapy in TYGRIS as of May 2011; and prior IS data in PML patients as of 5 September 2012. The analysis assumes that 55% of
natalizumab-treated MS patients were anti-JCV antibody positive and that all PML patients test positive for anti-JCV antibodies prior to the onset
and diagnosis of PML. The estimate of PML incidence in anti-JCV antibody negative patients is based on the assumption that all patients received
at least 1 dose of natalizumab. Assuming that all patients received at least 18 doses of natalizumab, the estimate of PML incidence in anti-JCV
antibody negative patients was generally consistent (0.1/1000; 95% CI 0.00–0.62).
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exchange might be justified [43].
Factors that appear to be associated with improved
survival in PML patients include younger age at diag-
nosis, lower pre-PML EDSS score, shorter time from
first symptoms to diagnosis and localised PML exten-
sion on MRI at diagnosis (i.e. unilobar vs. multilobar
or widespread lesions) [44]. Recently, several cases
have been reported in which PML has been detected by
MRI in asymptomatic patients [45,46]. In a study of pa-
tients with natalizumab-associated PML, 7% (21/298) were
asymptomatic at the time of diagnosis [14]. Most ofTable 1 Summary of positioning of natalizumab in the parad





Baseline therapy Glatiramer acetate Glatira
Interferon Interfethese (14/21) remained symptom-free over 13 months
of follow-up. Asymptomatic patients experienced sig-
nificantly less functional disability at diagnosis and at 6
and 12 months post-diagnosis compared with symp-
tomatic PML patients. Over time, EDSS scores were
consistently better in asymptomatic PML patients than
in symptomatic patients. As of 1 January 2013, 100% of
asymptomatic PML patients and 77% of symptomatic
PML patients were alive [14]. These preliminary data
suggest that functional outcomes and survival may be
better in patients whose PML is diagnosed before they
develop clinical symptoms.igm of MS therapies
sing-remitting MS
zumab
limod (depending on other risk factors: anti-JCV antibody status,
es mellitus, cardiac problems)
to other treatments (e.g. mitoxantrone, cyclophosphamide)
mer acetate Highly active patients:
ron Natalizumab
Fingolimod
Figure 3 Regional recommendations for maximising safety of natalizumab. CBC: complete blood count; CSF: cerebrospinal fluid; JCV: John
Cunningham virus; LFTs: liver function tests; PML: progressive multifocal leukoencephalopathy.
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The expert neurologists considered descriptions of sev-
eral clinical cases and discussed their management. They
then voted on a series of questions on the positioning of
natalizumab in the paradigm of MS therapies. Table 1
summarises the conclusions on the positioning of natali-
zumab relative to other MS therapies.
Regional recommendations
Figures 3, 4 and 5 show the algorithm developed during
the discussion. Natalizumab is recommended as an escal-
ation therapy in patients with breakthrough disease on the
basis of its established efficacy in Phase III studies. In
highly active MS, natalizumab is considered as a first-line
therapy for naive patients with disabling relapses in associ-
ation with MRI activity. Several factors including prior im-
munosuppressant therapy, anti-JCV antibody status and
patient choice may contribute to the selection of natalizu-
mab. A complete blood count and a cranial MRI scan
(within 3 months of starting natalizumab therapy) are rec-
ommended at baseline. This enables comparison withFigure 4 Regional recommendations for using natalizumab in anti-JCsubsequent scans that may be done to investigate the
cause of new or worsening neurological symptoms once
on natalizumab therapy. Figure 3 shows recommendations
for maximising the safety of natalizumab. Treatment
should be stopped if hypersensitivity reactions or persist-
ent anti-drug antibodies occur. If infusion reactions occur,
treatment can be continued with monitoring and pre-
medication. Treatment is discontinued in the event of
non-response, pregnancy, suspicion of PML, definite ad-
verse events or a change in the benefit–risk evaluation.
A low threshold to withhold natalizumab and investi-
gate with MRI and CSF testing is recommended when a
diagnosis of possible PML is entertained. If a thorough
neurological assessment cannot rule out PML, natalizu-
mab must be suspended and not restarted until a
disorder other than MS has been excluded with confi-
dence. Natalizumab can be resumed only if the diagno-
sis of PML is discounted [43].
The anti-JCV antibody test is used to assess anti-JCV
antibody status. It is recommended to obtain the test at
treatment initiation or during treatment with natalizumab,V antibody-negative patients. JCV: John Cunningham virus.
Figure 5 Regional recommendations for using natalizumab in anti-JCV antibody-positive patients. B/R: Benefit/risk; IS: immunosuppression;
JCV: John Cunningham virus.
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ment decision in the first 12–24 months. Anti-JCV anti-
body testing every 6 months and annual MRI scans are
recommended during natalizumab treatment (Figure 4).
Seronegative patients should continue treatment with
natalizumab. In seropositive patients, the expected bene-
fits of natalizumab treatment have to be weighed against
the risks. Clinical vigilance and follow-up MRI scans are
recommended as monitoring parameters (Figure 5). After
2 years of natalizumab therapy, monitoring should include
more frequent MRI scans (every 3–4 months), and the
benefit–risk ratio of natalizumab treatment should be
reassessed and discussed with patients. The increased risk
of PML with previous immunosuppressant use seems to
be independent of PML risk associated with duration of
natalizumab treatment. Risk stratification by previous im-
munosuppressant use and treatment duration must be
considered in a broader context that includes additional
factors such as benefits of treatment, risks of inadequately
treated MS or progression of the disease, and the relative
benefit–risk profiles of alternative treatments [13]. Anti-
JCV antibody status seems to be stable over time, with an
annual seroconversion rate of approximately 2–3% [39].
Specific education of physicians with respect to manage-
ment of PML is needed for all prescribers.
Conclusions
These recommendations have been developed by expert
neurologists in the MENA region through a process ofdiscussion and voting on key questions. They are
intended to guide neurologists in the region in selecting
appropriate MS patients for natalizumab treatment and
monitoring them to minimise the risk of PML and to
detect PML cases early as asymptomatic detection is as-
sociated with better outcomes.Abbreviations
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